Landscape Capital Management L.L.C. Increases Stake in Emergent BioSolutions Inc. (NYSE:EBS)

Landscape Capital Management L.L.C. grew its stake in Emergent BioSolutions Inc. (NYSE:EBS) by 39.5% during the 4th quarter, HoldingsChannel reports. The firm owned 23,595 shares of the biopharmaceutical company’s stock after buying an additional 6,682 shares during the quarter. Landscape Capital Management L.L.C.’s holdings in Emergent BioSolutions were worth $226,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in EBS. FMR LLC boosted its holdings in Emergent BioSolutions by 12.6% during the third quarter. FMR LLC now owns 129,099 shares of the biopharmaceutical company’s stock worth $1,078,000 after buying an additional 14,446 shares in the last quarter. Stifel Financial Corp purchased a new stake in shares of Emergent BioSolutions during the 3rd quarter worth about $96,000. State Street Corp grew its position in shares of Emergent BioSolutions by 864.7% during the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock valued at $15,960,000 after acquiring an additional 1,713,200 shares during the period. Wellington Management Group LLP increased its stake in shares of Emergent BioSolutions by 19.6% in the 3rd quarter. Wellington Management Group LLP now owns 136,289 shares of the biopharmaceutical company’s stock valued at $1,138,000 after purchasing an additional 22,295 shares in the last quarter. Finally, Barclays PLC raised its holdings in Emergent BioSolutions by 361.6% in the 3rd quarter. Barclays PLC now owns 39,308 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 30,792 shares during the period. Institutional investors and hedge funds own 78.40% of the company’s stock.

Emergent BioSolutions Price Performance

NYSE:EBS opened at $4.27 on Wednesday. The stock has a 50 day moving average of $7.04 and a two-hundred day moving average of $8.50. Emergent BioSolutions Inc. has a 12 month low of $1.82 and a 12 month high of $15.10. The firm has a market cap of $231.75 million, a P/E ratio of -1.04 and a beta of 2.14. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.40. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The firm had revenue of $194.70 million during the quarter, compared to the consensus estimate of $254.67 million. During the same period in the prior year, the company earned ($0.77) EPS. On average, analysts expect that Emergent BioSolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Emergent BioSolutions announced that its Board of Directors has initiated a share repurchase program on Monday, March 31st that authorizes the company to repurchase $50.00 million in shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase up to 19% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

Several analysts have commented on EBS shares. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a report on Tuesday, April 1st. StockNews.com cut shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Wednesday, March 5th.

Insider Transactions at Emergent BioSolutions

In related news, Director Neal Franklin Fowler sold 35,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the sale, the director now owns 101,100 shares of the company’s stock, valued at approximately $589,413. This trade represents a 25.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.20% of the company’s stock.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.